Medicis does deal with Impax over Solodyn

Forbes noted that Medicis shares were higher after a deal with Impax over the Hatch-Waxman challenge to acne drug Solodyn.

An interesting comment in the story: "...the payment to Impax may "raise eyebrows" from regulatory agencies, he added, though it appears structured as part of the broader partnership. (...) the companies will jointly develop five dermatology products, including an advanced form of Solodyn, with Impax receiving $40 million on signing and up to $23 million in future payments."